Across TCGA pan-cancer cohorts, ZNF528 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZNF528 data layer compared with 25 for mass-spec protein.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher ZNF528 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF528 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
CESC, ESCA, and SKCM are the cancer types where ZNF528 Mutation most reproducibly stratifies survival.